Mr. Todd Shapiro reports

RED LIGHT HOLLAND EXPANDS NEW ZEALAND PARTNERSHIP WITH ALLU THERAPEUTICS TO ADVANCE ACCESS TO FILAMENT HEALTH'S GMP-COMPLIANT PEX010 BOTANICAL PSILOCYBIN DRUG CANDIDATE

Following Red Light Holland Corp.'s acquisition of Filament Health Corp., the company has expanded its pharmaceutical-grade manufacturing, regulatory and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010. The company is pleased to announce it has signed an addendum to its existing supply agreement with Allu Therapeutics Ltd., expanding the relationship in New Zealand to include the supply of Filament Health's good-manufacturing-practice-compliant PEX010 botanical psilocybin drug candidate.

The addendum formally adds Filament Health as a supplying affiliate under the agreement and expands available PEX010 formats to include a standardized microdose format of PEX010. To the company's knowledge, this represents the first GMP-compliant standardized microdose format of a botanical psilocybin drug candidate, differentiating it from synthetic formulations and non-standardized products currently available in the market.

The expanded agreement reflects Red Light's continuing commitment to advancing access to GMP-compliant PEX010 through a quality-controlled and regulatory-conscious supply framework designed to support research initiatives and regulated access pathways over time. New Zealand's evolving regulatory framework, which permits authorized psychiatrists to prescribe psilocybin to treatment-resistant patients on a case-by-case basis, represents an important step toward expanding patient access and supporting responsible medicinal use initiatives within the region.

"This expanded agreement with Allu reflects the strategic value of the Filament acquisition," said Todd Shapiro, chief executive officer and director of Red Light. "By introducing Filament Health's GMP-compliant PEX010 into this partnership, we are advancing broader access while reinforcing PEX010's position as a leading botanical psilocybin drug candidate for qualified partners and research initiatives globally."

"We are pleased to deepen our relationship with Red Light and Filament Health," said Mark Dye, founder and chief executive officer of Allu Therapeutics. "Access to GMP-compliant, standardized PEX010 strengthens our ability to support and sell to researchers and doctors as we work toward the responsible advancement of regulated access initiatives and future therapeutic applications."

PEX010 is Filament Health's patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.

About Red Light Holland Corp.

Red Light is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.

About Allu Therapeutics Ltd.

Allu Therapeutics was a spunout of NUBU -- New Zealand's largest medicinal cannabis distributor in 2024. The company's focus is the distribution of psilocybin and other next-generation medicines in Australasia and beyond.

We seek Safe Harbor.